Evidence Grade A — Regulatory approved. 860 published studies. 117 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Romiplostim (sold as Nplate) stimulates the bone marrow to produce more platelets — the blood cells essential for clotting. It is approved for immune thrombocytopenia (ITP), a condition where the immune system destroys platelets faster than the body can replace them, leaving patients at risk of dangerous bleeding. Given as a weekly injection with dose adjusted based on platelet counts.
Romiplostim is also known by these brand and alternate names:
860 published studies: 632 human, 31 animal, 22 in-vitro, 218 reviews
Romiplostim is marketed as Nplate (approved August 2008) for chronic immune thrombocytopenia in adults and children who have not responded adequately to other treatments. Administered as a weekly subcutaneous injection with dose adjusted to maintain platelet counts.
In clinical trials, 38–56% of patients achieved durable platelet responses, and long-term extension data over five years showed sustained effectiveness. Romiplostim transformed ITP management by offering an alternative to immunosuppression and splenectomy (surgical removal of the spleen). Potential risks include bone marrow fibrosis with long-term use (generally mild and reversible) and rebound thrombocytopenia if treatment is stopped abruptly.
The body normally regulates platelet production through thrombopoietin (TPO), a hormone that tells bone marrow cells to make more platelets. In ITP, platelet destruction outpaces production. Romiplostim activates the same TPO receptor on bone marrow megakaryocytes (the cells that produce platelets), stimulating them to multiply, mature, and release platelets into the blood. Despite activating the TPO receptor, romiplostim has no structural resemblance to natural TPO — it was discovered through random peptide library screening — which means it does not trigger the antibody responses that plagued earlier TPO-like drugs.
Clinical trials showed durable platelet responses in 38–56% of patients, and long-term data extending over ten years confirm sustained effectiveness. Romiplostim transformed ITP management by offering an alternative to immune-suppressing drugs and splenectomy (surgical removal of the spleen, which was previously a common approach for resistant ITP). Potential risks include mild bone marrow fibrosis with long-term use (generally reversible after stopping), blood clotting events, and rebound low platelets if treatment is stopped abruptly. A risk management programme (NEXUS) is required. There is a small background rate of blood cancers (MDS/AML) in ITP patients, and whether romiplostim contributes to this risk remains unclear from current data.
PeptideTrace tracks 117 registered clinical trials for Romiplostim sourced from ClinicalTrials.gov.
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Preoperative Use of Romiplostim in Thrombocytopenic Patients Undergoing Cardiac Surgery.
UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia
A Multicenter Clinical Study of Romiplostim N01 in the Treatment of Sepsis-related Thrombocytopenia
Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA
FDA ORIG 1
EMA Marketing Authorisation
Health Canada Market Authorisation
FDA SUPPL 26
FDA SUPPL 32
FDA SUPPL 36
FDA SUPPL 28
FDA SUPPL 73
FDA SUPPL 77
FDA SUPPL 106
FDA SUPPL 121
FDA SUPPL 141
FDA SUPPL 155
FDA SUPPL 156
FDA SUPPL 160
FDA SUPPL 163
FDA SUPPL 164
FDA SUPPL 169
FDA SUPPL 167
FDA SUPPL 170
FDA SUPPL 168
FDA SUPPL 172
FDA SUPPL 176
Romiplostim is an Fc-peptide fusion (peptibody): two copies of 14-AA TpoR-binding peptide (IEGPTLRQWLAARA) linked to IgG1 Fc domain. MW ~59 kDa. Identified by phage display, no TPO homology. Four peptide copies per molecule interact with two TpoR dimers. SC 1-10 mcg/kg weekly, titrated. Half-life 1-34 days (median 3.5).
Binds and activates thrombopoietin receptor (TpoR/c-Mpl) on megakaryocytes. Triggers JAK2/STAT3/STAT5, MAPK, PI3K/AKT, ERK pathways. Stimulates megakaryocyte proliferation, differentiation (2N to 64N+), and proplatelet formation. IgG1 Fc provides FcRn-mediated recycling for weekly dosing.
Marketed as Nplate. Approved August 22, 2008. Splenectomized (N=63): durable response 38% vs. 0% (P=0.0013). Non-splenectomized (N=62): 56% vs. 0% (P<0.0001). >5-year extension: sustained platelets 100,000-200,000/mcL. Indications: chronic ITP (insufficient response to first-line); newly diagnosed ITP when first-line contraindicated.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection. In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
Daptomycin is marketed as Cubicin (approved September 2003). It is indicated for complicated skin and soft tissue infections and S. aureus bloodstream infections including right-sided endocarditis. Administered as a once-daily intravenous infusion. A key limitation is that daptomycin cannot be used for pneumonia — lung surfactant inactivates the drug. In the bacteraemia trial, daptomycin was non-inferior to vancomycin with significantly lower rates of kidney problems (11% versus 26%). Creatine kinase (CK) levels must be monitored during treatment, as daptomycin can cause muscle toxicity. Generics became available after patent expiry, significantly reducing cost.
Comparisons
Evidence Reviews
Timelines
Regulatory Status
Deep Dives
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
